Tag: Cancer: Lung
FDA Approves Alecensa for ALK-Positive NSCLC
Drug is designed to block the effects of the ALK protein
FDA Approves Portrazza for Advanced Squamous NSCLC
Drug is designed to block activity of epidermal growth factor receptor protein
About Half of Pulmonologists Tend to Offer LDCT Screening
Overall, 52.4 percent have propensity for guideline-concordant low-dose CT screening
Surgery Can Benefit ‘Ineligible’ High-Risk Lung Cancer Patients
May be a treatment option for patients previously deemed ineligible
CRT May Be Preferred Strategy for Elderly With Lung Cancer
Increased survival for chemoradiotherapy versus chemotherapy in limited-stage, small-cell lung cancer
Report Details Benefits, Risks of Nivolumab for Squamous NSCLC
Benefit-risk summary shows beneficial effects for patients with metastatic SQ NSCLC
FDA Approves Expanded Use of Opdivo in Advanced Lung Cancer
Demonstrates survival benefit in both squamous and non-squamous non-small-cell lung cancer
Most Cancer Patients Believe Surgery Will Be Curative
Findings even among patients with stage IV lung, colorectal cancer
Palliative Radiotherapy Often Overused in Stage IV NSCLC
Not proven to further improve symptoms or quality of life; can have significant side effects
FDA Approves Keytruda for Advanced NSCLC
Approved for use with PD-L1 IHC 22C3 pharmDx test
